NCT03590054: A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

NCT03590054
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only Microsatellite Instability-High (MSI-H) tumors are eligible
Exclusions: Patients with active, unstable, or untreated central nervous system (brain) or leptomeningeal metastases; Leptomeningeal metastases are excluded regardless of clinical stability- see trial for details
https://ClinicalTrials.gov/show/NCT03590054

Comments are closed.

Up ↑